Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun melsungen ag, nemecko - elektrolyty - 76 - infundibilia

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - svalová atrofia, spinálna - iné lieky na poruchy muskuloskeletálneho systému - zolgensma je indikovaný na liečbu:pacienti s 5q chrbtice svalová atrofia (sma) s bi-allelic mutácia v smn1 génu, a klinická diagnóza sma typ 1, orpatients s 5q sma s bi-allelic mutácia v smn1 génu, a až 3 kópie smn2 génu.

Európska únia - slovenčina - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonín - sleep initiation and maintenance disorders; autistic disorder - psycholeptika - slenyto je indikovaný na liečbu nespavosti u detí a dospievajúcich vo veku 2-18 s autizmus spektrum poruchy (asd) a / alebo smith-magenis syndróm, kde spánku hygienické opatrenia boli nedostatočné.

Európska únia - slovenčina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Európska únia - slovenčina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - orkambi tablety sú uvedené pre liečbu cystickej fibrózy (cf) u pacientov vo veku 6 rokov a starších, ktorí sú homozygous pre f508del mutácie v cftr géne. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Európska únia - slovenčina - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - cryopyrin-spojené periodické syndrómy - imunosupresíva - rilonacept regeneron je indikovaný na liečbu periodické syndrómy asociované s kryopyrínom (caps) s ťažkými príznakmi, vrátane familiárnej studené auto-zápalový syndróm (fcas) a muckleovho-studne syndróm (mws) u dospelých a detí vo veku 12 rokov a staršie.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer limited - celecoxib - adenomatózna polypóza coli - antineoplastické činidlá - onsenal je indikovaný na zníženie počtu adenomatóznej Črevné polypy v familiárnej adenomatóznej polypózy (fap), ako doplnok chirurgia a ďalšie endoskopické sledovanie (pozri časť 4. Účinok onsenal vyvolaných zníženie polyp záťaž na riziko črevnej rakovina nebola preukázaná (pozri časť 4. 4 a 5.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

aspen pharma trading limited, Írsko - chlorambucil - 44 - cytostatica

Európska únia - slovenčina - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminokyselinový metabolizmus, vrodené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.